Vanguard Personalized Indexing Management
HUMA icon

Vanguard Personalized Indexing Management’s Humacyte HUMA Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,442
Closed -$9.97K – 2293
2026
Q1 		$9.97K Buy
16,442
+4,326
+36% +$4.5K ﹤0.01% 2154
2025
Q4 		$11.6K Sell
12,116
-2,158
-15% -$3.06K ﹤0.01% 1960
2025
Q3 		$24.8K Buy
14,274
+39
+0.3% +$76 ﹤0.01% 1958
2025
Q2 		$29.8K Buy
+14,235
New +$27.3K ﹤0.01% 1876

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Personalized Indexing Management's HUMA Position: Q2 2026 in Review

Vanguard Personalized Indexing Management sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 16,442 shares — an estimated $9.97K sold.

Vanguard Personalized Indexing Management first reported a position in HUMA in Q2 2025 and held it in 4 quarters. The position peaked at $29.8K in Q2 2025. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Vanguard Personalized Indexing Management reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 16,442 Humacyte shares in Q2 2026, an estimated $9.97K.
  • Vanguard Personalized Indexing Management first reported a position in Humacyte in Q2 2025 and held it in 4 quarters.
  • Vanguard Personalized Indexing Management's Humacyte position peaked at $29.8K in Q2 2025.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.